<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261598</url>
  </required_header>
  <id_info>
    <org_study_id>CHB06-02</org_study_id>
    <nct_id>NCT01261598</nct_id>
  </id_info>
  <brief_title>Predictive Value of FDG-TEP During Radiotherapy or Chemo-radiotherapy in Patients With NCSC on the One-year Survival</brief_title>
  <acronym>RTEP2</acronym>
  <official_title>Predictive Value of FDG-TEP During Radiotherapy (RT) or Chemo-radiotherapy (CRT) in Patients With Non Small Cell Lung Cancer on the One-year Survival</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The poor prognosis in the early-stage of lung cancer is due to potential worsening of the&#xD;
      disease (local relapse, metastasis), to insufficient efficacy and toxicity of actual&#xD;
      treatments.&#xD;
&#xD;
      FDG-PET is a medical imaging modality allowing the quantification of the tumour glucose&#xD;
      consumption. Then, this exam is used for pathology staging, target volume definition for RT,&#xD;
      and treatment efficiency few months after RT or CRT. Our assumption is that an FDG-PET exam&#xD;
      during the course of the RT or CRT might be predictive of the treatment efficiency few months&#xD;
      later.&#xD;
&#xD;
      In this study, the investigators propose to perform 4 FDG-PET: first &quot;PET1&quot; before&#xD;
      radiotherapy, second &quot;PET2&quot; during the radiotherapy (see RTEP1), third and fourth &quot;PET3&quot;&#xD;
      &quot;PET4&quot; 3month and 12 month after the therapy.&#xD;
&#xD;
      The investigators will investigate the performances of FDG-PET performed during the RT or CRT&#xD;
      for the prediction of the one-year patient heath outcome. If the predictive value of TEP2 is&#xD;
      confirmed, the investigators would be able to optimize the planning treatment during the&#xD;
      course of the therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV max from FDG PETScan</measure>
    <time_frame>Baseline - 5 Weeks after begining of radiotherapy- 3 months after end of radiotherapy- 1 year afterwards</time_frame>
    <description>Measure of FDG-TEP uptake variation (SUV max) to assess predictive value of FDG-TEP during radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of several optimized radiotherapy scenary according to the quantification of the tumour glucose consumption during radiotherapy</measure>
    <time_frame>after the completion enrollment date</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Lung Cancer</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with curative and exclusive radiotherapy (60 Gy minimum), with possibly prior chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient treated with concomitant chemotherapy and radiotherapy (60 Gy minimum), with possibly prior chemotherapy chemotherapy Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Positron Emission Tomography</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>PET scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  WHO performance status &lt;2&#xD;
&#xD;
          -  Measurable disease, defined as at least one lesion that can be accurately measured in&#xD;
             at least one dimension (â‰¥ 10 mm with spiral CT scan)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Baseline fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scan without&#xD;
             any target lesion&#xD;
&#xD;
          -  Unable to under PET CT evaluation&#xD;
&#xD;
          -  other concurrent investigational agents&#xD;
&#xD;
          -  No Planning to undergo curative intent radiotherapy&#xD;
&#xD;
          -  familial, social, geographic, or psychological conditions that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  Prior malignancy progressive disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard DUBRAY, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>November 19, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>PET Scan</keyword>
  <keyword>Non-Small-Cell Lung Carcinoma</keyword>
  <keyword>Radiation Oncology</keyword>
  <keyword>SUV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

